LEVALBUTEROL solution

Страна: США

мова: англійська

Джерело: NLM (National Library of Medicine)

Активний інгредієнт:

LEVALBUTEROL HYDROCHLORIDE (UNII: WDQ1526QJM) (LEVALBUTEROL - UNII:EDN2NBH5SS)

Доступна з:

NuCare Pharmaceuticals,Inc.

Адміністрація маршрут:

RESPIRATORY (INHALATION)

Тип рецепту:

PRESCRIPTION DRUG

Терапевтичні свідчення:

Levalbuterol inhalation solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol inhalation solution is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. Reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see Warnings and Precautions ( 5.6) ]. Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to asthma medication, including levalbuterol inhalation solution, during pregnancy. To enroll in MotherToBaby Pregnancy Studies’ Asthma & Pregnancy Study or for more information about the registry, call 1-877-311-8972 or visit www.mothertobaby.org/ongoing-study/asthma. Risk Summary There are no adequate and well-controlled studies of levalbuterol inhalation solution in pregnant wome

Огляд продуктів:

Levalbuterol inhalation solution, USP, 1.25 mg contains 1.25 mg of levalbuterol (as 1.44 mg of levalbuterol HCl) and is available in cartons of 25 unit-dose LDPE vials (NDC 68071-2340-5). Storage: Store levalbuterol inhalation solution, USP in the protective foil pouch at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature]. Protect from light and excessive heat. Keep unopened vials in the foil pouch. Once the foil pouch is opened, the vials should be used within 2 weeks. Vials removed from the pouch, if not used immediately, should be protected from light and used within 1 week. Discard any vial if the solution is not colorless.

Статус Авторизація:

Abbreviated New Drug Application

Характеристики продукта

LEVALBUTEROL- LEVALBUTEROL SOLUTION
NUCARE PHARMACEUTICALS,INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
LEVALBUTEROL INHALATION SOLUTION
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
LEVALBUTEROL INHALATION SOLUTION.
LEVALBUTEROL INHALATION SOLUTION
INITIAL U.S. APPROVAL: 1999
INDICATIONS AND USAGE
Levalbuterol inhalation solution is a beta
-adrenergic agonist indicated for:
Treatment or prevention of bronchospasm in adults, adolescents, and
children 6 years of age and older with reversible
obstructive airway disease. ( 1)
DOSAGE AND ADMINISTRATION
FOR ORAL INHALATION ONLY ( 2)
_Children 6 to 11 years old_: 0.31 mg administered three times a day,
by nebulization. Routine dosing should not exceed
0.63 mg three times a day. ( 2)
_Adults and Adolescents ≥12 years old_: 0.63 mg administered three
times a day, every 6 to 8 hours, by nebulization. The
maximum recommended dose is 1.25 mg three times a day. ( 2)
For use with a standard jet nebulizer (with a face mask or mouthpiece)
connected to an air compressor. ( 2)
DOSAGE FORMS AND STRENGTHS
Inhalation Solution (unit-dose vial for nebulization): 0.31 mg/3 mL,
0.63 mg/3 mL and 1.25 mg/3 mL. ( 3)
CONTRAINDICATIONS
Hypersensitivity to levalbuterol or racemic albuterol. ( 4)
WARNINGS AND PRECAUTIONS
Life-threatening paradoxical bronchospasm may occur. Discontinue
levalbuterol inhalation solution immediately and
treat with alternative therapy. ( 5.1)
Need for more doses of levalbuterol inhalation solution than usual may
be a sign of deterioration of asthma and requires
reevaluation of treatment. ( 5.2)
Levalbuterol inhalation solution is not a substitute for
corticosteroids. ( 5.3)
Cardiovascular effects may occur. Consider discontinuation of
levalbuterol inhalation solution if these effects occur. Use
with caution in patients with underlying cardiovascular disorders. (
5.4)
Excessive use may be fatal. Do not exceed recommended dose. ( 5.5)
Immediate hypersensitivity reactions may o